PRR35

Across TCGA pan-cancer cohorts, PRR35 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRR35 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher PRR35 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRR35 expression acts as an unfavorable survival marker.

PAAD, STAD, and COAD are the cancer types where PRR35 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.060	0.641	<.001	24	view →
STAD	DFS	Median	All	0.149	0.710	<.001	18	view →
COAD	DFS	Median	All	0.220	0.793	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRR35–PAAD (OS)

Open the PAAD breakdown →